Mymetics (OTCMKTS:MYMX) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.
Insider & Institutional Ownership
0.8% of Mymetics shares are owned by institutional investors. Comparatively, 7.2% of Oncobiologics shares are owned by institutional investors. 54.2% of Mymetics shares are owned by insiders. Comparatively, 11.5% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Mymetics and Oncobiologics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Mymetics and Oncobiologics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares Mymetics and Oncobiologics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mymetics||$1.14 million||6.98||-$4.93 million||N/A||N/A|
|Oncobiologics||$3.81 million||0.00||-$38.84 million||N/A||N/A|
Mymetics has higher earnings, but lower revenue than Oncobiologics.
Risk and Volatility
Mymetics has a beta of -0.71, meaning that its share price is 171% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500.
Mymetics beats Oncobiologics on 4 of the 7 factors compared between the two stocks.
Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for Mymetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymetics and related companies with MarketBeat.com's FREE daily email newsletter.